Foundation models, virtual cells, AI-designed molecules, self-driving labs, and the companies putting them to work.
SynBioBeta 2027 May 3-6, San Jose, California

George
Church
Harvard Medical School
SAB

Alex
Rives
CZI Biohub
Head of Science

Aliza
Apple
Eli Lilly
Vice President of Catalyze360 AI/ML

Patrick
Hsu
Arc Institute
Co-Founder

Stef
van Grieken
Cradle
CEO

Jorge
Reis-Filho
Foresite Labs
CSO, Operating Partner

Eli
Black
Xellsion.AI
Founder and CEO

Yogev
Debbi
Mana.bio
Co-Founder & CEO

Eric
Kelsic
Dyno Therapeutics
CEO & Founder

AIxBIO
Biology is becoming computable, and the pipeline is compressing.
Biology is becoming computable, and the consequences run the length of the field.
At the foundation, virtual cells and biological foundation models are replacing incomplete mental models with systems that predict rather than guess. Downstream, that predictive power is compressing the therapeutic pipeline: targets validated faster, molecules and proteins designed generatively, toxicity anticipated before the clinic, delivery engineered to reach the right tissue. Around it, labs are learning to run themselves, with autonomous hardware and AI agents closing the loop between hypothesis and evidence without waiting on human pace. And at the far end, where good candidates still fail, AI is reshaping trial design, patient stratification, and the real-world evidence that determines whether a therapy actually helps anyone.
This theme follows that arc from first principles to patient outcomes, and asks the question the field keeps circling: where is it real, and where is it still a promise?
Where youโll meet the people
building the next decade of AI-driven biology.
Meet the Sponsors & Exhibitors

NunaBio

Anocca AB

Origenity

Twist Bioscience

Cradle

Matterworks

Ansa Biotechnologies

Centivax

Arzeda

Procter & Gamble

Pumpkinseed
Bunker Bio

Federov

Genoa Ventures

Dyno Therapeutics

EverGlade Consulting

Genyro

Aminoverse

GenScript

Acrisure

Lab Thread

Gator Bio

Bio Base Europe Pilot Plant

Joint BioEnergy Institute (JBEI)

Bold View Capital

Chromatin Bioscience

DoriNano Inc

Evonik

GRIDX

Hamilton Company

New England Biolabs

Omega Bio-Tek

Solaris Biotech by Donaldson

Genomic Intelligence

Ingenza

Substrate Bio

Agentic Bio

IKA Works

Andgel Industrial (Shanghai) Co., Ltd.

Xellsion.AI

Flock Bio

Wexford Connect Labs

Sunthetics AI

Talaria Biosciences

Miibio

Angstrom Innovation

Frontiers

The Bioforge

Twig

3dr

Bay Area Cancer Connections

Korea Institute Of Science And Technology
Why People Keep Coming Back

โ
SynBioBeta is a whoโs who of AI and biology. This is where the future is being built, so don't miss it.
Eric Schmidt
Former CEO


โ
Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal.
Surge Biswas
Founder


โ
I met Algen at SynBioBeta and later invested in the company. It's exactly the kind of connection that makes the community so valuable.
Bill Tai
Co-founder


โ
For every single fund at Boom Capital, one of our best companies has come directly from SynBioBeta. I met Mammoth Bio at SynBioBeta, and I met Nabla Bio at SynBioBeta.
Celestine Schnugg
Founder

Advance Discount Ends Midnight Friday, November 20. Lock In Your Rate Now.
All passes are fully refundable.
Students: Join our Next-Generation Leaders Program
Secure Your Spot in the Exhibit Hall


